darbepoetin alfa + recombinant human erythropoietin (rHuEPO)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gynecological Malignancies
Conditions
Gynecological Malignancies, Genital Neoplasms, Female, Anemia
Trial Timeline
Oct 1, 2002 → Dec 1, 2003
NCT ID
NCT00121030About darbepoetin alfa + recombinant human erythropoietin (rHuEPO)
darbepoetin alfa + recombinant human erythropoietin (rHuEPO) is a phase 2 stage product being developed by Amgen for Gynecological Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT00121030. Target conditions include Gynecological Malignancies, Genital Neoplasms, Female, Anemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00121030 | Phase 2 | Completed |
| NCT00120679 | Phase 2 | Completed |
Competing Products
3 competing products in Gynecological Malignancies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1 | 33 |
| Vigil + Atezolizumab | Roche | Phase 2 | 52 |
| Ciprofol + Propofol | Haisco Pharmaceutical Group | Phase 3 | 74 |